International Flavors & Fragrances (IFF) Q4 2024 earnings summary

Executive summary

• Achieved $11.5 billion in 2024 sales, with 6% currency-neutral growth and improved profitability driven by operational discipline, business model changes, and innovation focus.

• Adjusted operating EBITDA reached $2.21 billion, up 16% year-over-year, with margin expansion and strong execution across all business units.

• Strategic focus on biotechnology, R&D, and commercial capabilities, with increased CapEx and talent development to drive long-term growth.

• Board evolution with new members and chair, and enhanced talent through internal promotions and external appointments.

• Completed Cosmetics Ingredients divestiture and announced Pharma Solutions sale as part of ongoing portfolio optimization.

Financial highlights

• Q4 2024 revenue was $2.77 billion, up 6% currency-neutral, with mid-single-digit volume growth across all businesses.

• Q4 adjusted operating EBITDA was $471 million, up 5%, with a 30 bps margin expansion.

• Full-year cash flow from operations was $1.07 billion; CapEx was $463 million (4% of sales); free cash flow totaled $607 million.

• Gross debt at year-end was $9 billion, down over $1 billion year-over-year; net debt-to-credit adjusted EBITDA improved to 3.8x.

• $514 million in dividends distributed in 2024.

Outlook and guidance

• 2025 sales expected at $10.6–$10.9 billion, 1–4% currency-neutral growth, with 5% adverse impact from divestitures and 4% from FX.

• 2025 adjusted operating EBITDA guidance: $2–$2.15 billion, 5–10% growth currency-neutral, driven by gross margin expansion and productivity.

• CapEx to increase to ~6% of sales in 2025, with half for maintenance and the rest for growth, deferred investments, and digital transformation.

• Free cash flow for 2025 expected at $500 million (or $850 million excluding Pharma divestiture taxes).

• Net debt-to-credit adjusted EBITDA target below 3x post-Pharma Solutions sale, expected in H1 2025.